ASH 2019   |  December 9, 2019   Axi-Cel Improves OS in Patients with Refractory B-Cell Lymphoma The CAR T-cell therapy axicabtagene ciloleucel induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma. Read more   ADVERTISEMENT   Off-The-Shelf Immunotherapy Product Induces Positive Response in Patients with NHL Mosunetuzumab generated durable responses in patients with highly refractory non-Hodgkin lymphomas. Read more